Wire · opportunities
Pancreatic cancer drug may hold promise for lung cancer as well, early study suggests
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 September 2026 · Fusion42 review
An early clinical study shows that daraxonrasib, a drug recently approved for advanced pancreatic cancer, may reduce tumor burden in non-small cell lung cancer patients with RAS mutations, though further late-stage trials are needed before FDA approval for lung cancer treatment.
This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.
◆ ◆ The Wire takeaway
You can explore patient groups with RAS mutations as a new market now that a pancreatic cancer drug shows lung cancer potential. Expect a regulatory review deadline that opens a window for late-stage trials and accelerated approval.
◆ Coverage
48 sources · first reported 26 Aug 2026 · latest 16 Oct 2026
◆ Related on Wire
◆ Topics